Summary This latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H1 2020, provides an overview of the Vitiligo (Dermatology) pipeline landscape.
Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 9 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology). - The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis - Pipeline Review, H2 2020, provides an overview of the Systemic Sclerosis (Immunology) pipeline landscape. Scleroderma is a group of rare...
Thalassemia - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2020, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders...
Dystrophin - Pipeline Review, H2 2020 Summary According to the recently published report ’Dystrophin - Pipeline Review, H2 2020’; Dystrophin (DMD) pipeline Target constitutes close to 50 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes. Dystrophin...
Optic Neuropathy - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H2 2020, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape. Optic neuropathy is an inherited form of vision...